Jessica W. Aisenbrey
jessica.aisenbrey.wg11@
wharton.upenn.edu Princeton University, Princeton, NJ B.A., Magna Cum Laude, Comparative Literature, 2005 Harvard University, John F. Kennedy School of Government, Cambridge, MA M.P.A. Candidate, 2012 Fulbright Scholar 2006
An opportunity in a health care IT/services company working to lower costs and improve quality of health care delivery.
OptumHealth Care Solutions, Golden Valley, MN
Strategy and Business Development Intern, Summer 2010
Evaluated acquisition opportunities in health care services delivery. Developed a financial model to proj- ect value creation and key profitability drivers. Evaluated potential impact of healthcare reform legislation. Presented recommendations to CFO and business development leadership team. Helped with preparation of CEO’s presentations to government and public policy leaders.
Public Health Solutions, New York, NY Project Coordinator, 2007-2009; Public Health Fellow, 2005-2006 Initiated and led a multi-disciplinary team of 15 to improve clinical data reporting mechanisms across 7 women’s health centers in New York City, which increased grant reporting accuracy on over 50% of measures. Conducted patient flow analysis across women’s health centers to reduce wait time and improve operational efficien- cy. Managed annual $1.2M family planning marketing grant. Initiated first public awareness radio ad campaign, resulting in 11% increase in new family planning patients.
Elizabeth A. Almasi
elizabeth.almasi.wg11@
wharton.upenn.edu
Stanford University, Stanford, CA B.A., Honors, Economics, 2006
University of Pennsylvania, School of Medicine, Philadelphia, PA MD Candidate, 2011 Frank H. Buck Scholar, 2002-2011
Roy Amariglio, Ph.D.
roy.amariglio.wg11@
wharton.upenn.edu Tel Aviv University, Tel Aviv, Israel B.Sc., Biology and Chemistry, 2001 Weizmann Institute of Sciences, Rehovot, Israel Ph.D., Molecular Genetics, 2009
An opportunity to use my clinical and business expertise to improve the delivery of health care, especially through the use of technology.
McKinsey & Company, Florham Park, NJ Summer Associate, Summer 2010 Outlined business and technological requirements for a government entity to implement the Patient Protection and Affordable Care Act. Highlighted strategic options for interactions between companies and government agencies affected by health care reform and created high level timelines for implementation of new initiatives.
An opportunity to combine my scientific and business expertise to create value in the life-sciences industry.
Life Technologies, Carlsbad, CA Corporate Development Associate, Summer 2010
Coordinated due diligence and participated in all aspects of Life Technologies’ acquisition of Ion Torrent for $725M, including term sheet and deal structure negotiations, financial modeling and preparation of diligence reports for senior manage- ment and board members. Developed 5-year growth plan to expand $40M business segment. Conducted industry research and technical diligence, analyzed market dynamics and competitive landscape and identified targets for in licensing and M&A.
Market Bridges, Tel Aviv, Israel Associate, 2007-2009
Member of team that executed $20M investment in biotechnology company. Identified and evaluated life science investment opportunities. Conducted industry research, financial modeling and technical diligence. Evaluated strategic options for client and supported client’s senior management on potential M&A and licensing transactions.
Weizmann Institute of Sciences, Rehovot, Israel
Research Associate, 2005-2009 Led a team of 5 in a research project on cartilage degeneration. Developed animal models and identified potential molecules to treat Osteoarthritis.
6
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40